What it's for (Indications)
- Ribavirin is primarily indicated for the treatment of chronic hepatitis C (HCV) patients, typically as part of a combination antiviral therapy.
- Local Pakistani data also suggests its use for viral infections of the respiratory tract, an indication not detailed in the provided US FDA profile.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Ribavirin capsules are administered orally, typically with food, and dosed based on patient body weight. Capsules should not be opened, crushed, or broken. For adults in combination with PegIntron, the recommended dose ranges from 800 mg to 1,400 mg daily, given in two divided doses. For interferon alpha-naïve patients with genotype 1 HCV, the treatment duration is 48 weeks. Therapy discontinuation should be considered if an insufficient viral response (less than a 2 log 10 drop or loss of HCV-RNA) is observed by 12 weeks. Dose adjustments or discontinuation are recommended for specific adverse reactions or renal impairment. |
Safety & Warnings
Common Side Effects
- Common adverse reactions (40% or greater in adults) include injection site reaction, fatigue/asthenia, headache, rigors, fevers, nausea, myalgia, and anxiety/emotional lability/irritability.
- Serious adverse reactions include Embryo-Fetal Toxicity, Anemia (with hemolytic anemia occurring in over 10% of adult patients), Pancreatitis, Pulmonary Disorders, Ophthalmic Disorders, Dental and Periodontal Disorders, and potential Impact on Growth in Pediatric Patients.
- Specific common reactions in pediatric patients are noted to occur in greater than 25%.
Serious Warnings
- Black Box Warning: WARNING: EMBRYO-FETAL TOXICITY, HEMOLYTIC ANEMIA, and MONOTHERAPY NOT RECOMMENDED. Ribavirin exhibits significant teratogenic and embryocidal effects across all tested animal species. Given its prolonged multiple-dose half-life of 12 days and potential persistence in non-plasma compartments for up to 6 months, ribavirin therapy is strictly contraindicated in pregnant women and in male partners of pregnant women. Rigorous and effective contraception must be utilized by both male and female patients during treatment and for at least 6 months following its discontinuation.
- Patients must be closely monitored for serious adverse effects such as Embryo-Fetal Toxicity, severe Hemolytic Anemia, Pancreatitis, Pulmonary Disorders, Ophthalmic Disorders, Dental and Periodontal Disorders, and potential negative impacts on growth in pediatric patients.
- Dose reduction or discontinuation may be necessary in case of certain adverse reactions or renal dysfunction.
- Prior medical consultation is essential for individuals with pre-existing cardiac, kidney, or liver disease.
- Use is contraindicated in women who are breastfeeding.
- Alcohol consumption should be strictly avoided during therapy.
How it Works (Mechanism of Action)
Ribavirin functions as an anti-HCV agent. Its mechanism involves complex actions such as inhibition of viral RNA synthesis and modulation of host immune responses, contributing to its antiviral effects, especially in combination regimens.